Meal timing tested for new drug TS-172 in healthy volunteers
NCT ID NCT07084961
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a drug called TS-172 in 16 healthy Japanese men to see if taking it before or after a meal changes how the body handles phosphorus and sodium. The trial is complete and focused on safety and basic effects, not on treating any disease. It provides initial data on how the drug works in the body.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- TS-172
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
16 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 39 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Japanese healthy adult males whose age is \>=18 and \<40 years at the time of obtaining informed consent 2. Subjects whose body mass index is \>=18.5 and \<25.0 at the screening test 3. Subjects who are judged by a principal investigator or a sub-investigator to be eligible for participation in the study based on the results at the screening test and before administration of the drugs used in the study 4. Subjects who have been informed of the clinical trial, understand the details of the trial, and give their written consent prior to participation in the trial Exclusion Criteria: 1. Subjects with medical history ineligible for participation in the study such as of respiratory, cardiovascular, gastrointestinal, hepatic, renal, urologic, endocrine, metabolic, hematologic, immunologic, dermatologic, neurologic, or psychiatric diseases 2. Subjects with medical history of disease (e.g., stomach or intestinal ulcers) or surgery (e.g., gastrectomy, gastric bandage, gastric bypass) that may affect the absorption of the drugs used in the study 3. Subjects who have been hospitalized with any treatment or undergone surgery within 12 weeks prior to receiving the drugs used in the study 4. Subjects with medical history of drug allergies (limited to severe symptoms such as anaphylaxis) or significant allergic predispositions (e.g., asthma that requires treatment) 5. Subjects who have used medications (including over-the-counter drugs) within 2 weeks prior to receiving the drugs used in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy adult male subjects are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Taisho Pharmaceutical Co., Ltd selected site
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.